Skip to main content
Fig. 5 | Biomarker Research

Fig. 5

From: Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia

Fig. 5

Sitravatinib efficiently suppresses the resistance mediated by FGF2 and FL. A-B The IC50 values of sitravatinib (S) and gilteritinib (G) for MV4-11 or MOLM13 cells in the absence/presence of FGF2 or FL. Error bars indicate mean ± standard error, n = 3 independent experiments. **P < 0.01, ***P < 0.001, ****P < 0.0001. C-F MV4-11 and MOLM13 cells were treated with sitravatinib or gilteritinib at indicated concentrations for 3 h, then FGF2 or FL (10 ng/mL) was added to the culture for incubation of 3 h. Cell lysates were immunoblotted to evaluate p-FLT3, p-STAT5, p-AKT and p-ERK 1/2. The densitometry ratio of p-AKT to AKT and p-ERK to ERK was assessed via ImageJ, and expressed as fold change compared with vehicle control

Back to article page